Halozyme Therapeutics | HALO - Gross Profit On Sales

Stock Price
69.45
Daily Change
0.23 0.33%
Monthly
-4.64%
Yearly
17.41%
Q1 Forecast
68.78

Halozyme Therapeutics reported $281.77M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amarin USD 22.21M 28.15M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Baxter International USD 577M 373M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cytokinetics USD 17.76M 15.82M Dec/2025
DBV Technologies USD 2.77M 33.21M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Intrexon USD -297K 167K Jun/2024
Ionis Pharmaceuticals USD 195M 40M Dec/2025
MannKind USD 78.31M 76.21M Dec/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 13.75M 650K Jun/2024
Pfizer USD 3.54B 7.61B Sep/2025
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
United Therapeutics USD 315.5M 286.6M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024